Selected article for: "HCQ treatment and PBMC dataset"

Author: Michael Jay Corley; Christopher Sugai; Michael Schotsaert; Robert E. Schwartz; Lishomwa C Ndhlovu
Title: Comparative in vitro transcriptomic analyses of COVID-19 candidate therapy hydroxychloroquine suggest limited immunomodulatory evidence of SARS-CoV-2 host response genes.
  • Document date: 2020_4_14
  • ID: 30x26ip7_14
    Snippet: Next, we sought to perform a more direct comparison of transcriptional differences observed by HCQ treatment of primary PBMC cells with transcriptional differences in a dataset of PBMC samples from SARS-CoV-2 infected individuals compared to uninfected controls. We analyzed RNA-seq data of PBMC samples author/funder. All rights reserved. No reuse allowed without permission......
    Document: Next, we sought to perform a more direct comparison of transcriptional differences observed by HCQ treatment of primary PBMC cells with transcriptional differences in a dataset of PBMC samples from SARS-CoV-2 infected individuals compared to uninfected controls. We analyzed RNA-seq data of PBMC samples author/funder. All rights reserved. No reuse allowed without permission.

    Search related documents:
    Co phrase search for related documents
    • HCQ treatment and PBMC cell: 1
    • HCQ treatment and RNA seq: 1, 2
    • HCQ treatment and uninfected control: 1
    • infected individual and RNA seq: 1, 2, 3
    • infected individual and SARS infected individual: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • infected individual and uninfected control: 1
    • PBMC cell and primary PBMC cell: 1
    • PBMC cell and RNA seq: 1, 2, 3, 4, 5, 6, 7
    • RNA seq and uninfected control: 1, 2, 3, 4